Every material Form 8-K Oric Pharmaceuticals, Inc. has filed with the SEC since July 30, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
ORIC Pharmaceuticals presented updated Phase 1b data for its enozertinib (ORIC-114) program at ESMO Congress 2026 on October 23, 2026, reporting an 84% investigator-assessed systemic response rate and a 70% investigator-assessed intracranial response rate in 26 patients with EGFR atypical NSCLC. The company plans to start a global Phase 3 trial, Redwood-1, in the first half of 2027. The filing contains clinical data only and no financial results, so the update's effect on shareholders depends on future trial outcomes and funding.
Investigator-assessed systemic ORR was 84% (21 of 25); BICR-assessed systemic ORR was 80% (20 of 25) as of the September 4, 2026 cutoff
BICR RANO-BM intracranial ORR was 67% (10 of 15), with a 40% (6 of 15) complete response rate
Six patients (23%) had Grade 3 treatment-related adverse events, all resolved with dose modifications; no Grade 4 or 5 events were reported
Redwood-1 Phase 3 trial plans to enroll approximately 360 patients, with initiation planned for the first half of 2027
ORIC Pharmaceuticals reported a second-quarter 2026 net loss of $41.5 million, up from $36.4 million a year earlier, as research and development spending rose. Loss per share narrowed to $0.38 from $0.47, but the filing shows a higher weighted-average share count, and the company said cash and investments of $387.6 million, including $59.9 million raised under its at-the-market program, fund operations into the second half of 2028.
Net loss was $41.5 million for the quarter ended June 30, 2026, versus $36.4 million a year earlier; loss per share was $0.38 versus $0.47.
R&D expenses rose to $36.3 million from $30.5 million, mainly due to external costs for rinzimetostat.
Cash, cash equivalents and investments totaled $387.6 million as of June 30, 2026, which the company expects to fund its operating plan into the second half of 2028.
The Himalayas-1 global Phase 3 trial of rinzimetostat was initiated, and a supply agreement with Bayer provides darolutamide for the trial at no cost.
ORIC Pharmaceuticals' board approved an amended and restated 2022 Inducement Equity Incentive Plan effective July 28, 2026, adding 1,100,000 shares for a total of 3,350,000 shares reserved for equity awards. The plan was adopted without stockholder approval under Nasdaq rules and is limited to inducement grants to new hires or acquisition-related awards, so it adds to potential future share issuance.
Board approved an additional 1,100,000 shares, bringing the total reserved under the Inducement Plan to 3,350,000 shares of common stock.
Approved effective July 28, 2026, and adopted without stockholder approval under Nasdaq Listing Rules.
Awards may be granted only to individuals not previously employees or non-employee directors, as an inducement to employment or, where permitted, in connection with a merger or acquisition.
The full plan is filed as Exhibit 10.1 to the 8-K.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Oric Pharmaceuticals, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →